AVANT has initiated a new development program that applies our proprietary bacterial vector technologies to the development of a single-dose, oral vaccine against Avian flu. The combination of conserved antigens together with its existing vaccine technologies, could lead to an Avian flu vaccine with product characteristics ideal for mass vaccinations: safe and effective, single-dose, oral, and storable at room temperature. AVANT is currently evaluating a number of Avian flu constructs in pre-clinical animal models to determine their immunogenicity and, if successful, would hope to select a vaccine candidate within 6-12 months.